Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02406222 | Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)(MUKseven) | active not recruiting | Phase 2 | 124 | University of LeedsOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 |
| clinicaltrials |
| NCT06715267 | Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)(VYP) | recruiting | — | 200 | University Hospital, BrestOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06716164 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04533217 | Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. | recruiting | N/A | 90 | Spine Centre of Southern DenmarkOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06534463 | Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)(MOTIVE) | recruiting | — | 500 | Ruijin HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03356262 | The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort(QUALITY) | active not recruiting | — | 630 | St. Justine's HospitalOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT03671018 | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 422 | Hoffmann-La RocheINDUSTRY | 5 | Nov 29, 2024 | clinicaltrials |
| NCT06245629 | Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | recruiting | — | 100 | Uppsala UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03449953 | Critical Care Outcomes of Hematologic Oncology Patients(COHO) | active not recruiting | — | 415 | Mount Sinai Hospital, CanadaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05396157 | Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study | active not recruiting | — | 813 | Mount Sinai Hospital, CanadaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04147533 | Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia(HALF) | active not recruiting | Phase 2 | 150 | Masaryk UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705725 | Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | not yet recruiting | Phase 1 | 38 | Carbiogene Therapeutics Co. Ltd.INDUSTRY | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | recruiting | N/A | 100 | Peking University People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702566 | The Effect of Serum Ferritin in irAE | recruiting | N/A | 1,500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04741945 | Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS | recruiting | Phase 2 | 40 | Kirsten GrønbækOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06588413 | Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan(FONDO-LOW) | recruiting | Phase 3 | 172 | Augusta UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06701344 | Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients(GOAL) | not yet recruiting | Phase 2 | 7 | Ruijin HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06698484 | To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)(CAR-T for NHL) | recruiting | Phase 2 | 20 | National University of MalaysiaOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia(TBI-1501) | active not recruiting | Phase 1 / Phase 2 | 21 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT05806099 | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL | recruiting | Phase 1 / Phase 2 | 132 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06566586 | A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma | recruiting | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06696833 | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06693973 | An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Early Phase 1 | 13 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(V-MIND) | recruiting | Phase 2 | 100 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | recruiting | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | recruiting | Phase 1 | 36 | Vincerx Pharma, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05156203 | Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | recruiting | Phase 1 | 30 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06643962 | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy | recruiting | N/A | 83 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06682156 | Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients | recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | active not recruiting | Phase 1 | 88 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04168502 | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | recruiting | Phase 3 | 414 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | recruiting | Phase 3 | 67 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04763928 | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax(ENABLE) | active not recruiting | Phase 2 | 101 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06644118 | A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 58 | Zhejiang UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04234061 | Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma(TARMAC) | active not recruiting | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2024source: clinicaltrials